Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06762964 · ClinicalTrials.gov registry record · Phase 2
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
A Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Single Ventricle Heart Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT06762964: Recruiting Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Single Ventricle Heart Disease, sponsored by Mayo Clinic.
NCT06762964 is a Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Single Ventricle Heart Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 27 participants, below the 9,876-participant average among 6 other HFpEF - Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06762964, a Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Single Ventricle Heart Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 6 months affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in adults with failing Fontan circulation.
Primary Outcome
Peripheral venous pressure (PVP) at rest will be determined by Stress Echocardiogram. Peripheral venous pressure (PVP) is measured in millimeters of mercury (mmHg).
Conditions Studied
Interventions
- DRUG Dapagliflozin tablet
- DRUG Placebo Tablet
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What NCT06762964 shows while recruiting
NCT06762964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 9,876-participant average among 6 other HFpEF - Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with HFpEF - Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Dapagliflozin tablet is the first listed.
NCT06762964 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06762964 about?
NCT06762964 is a clinical study titled "CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation". The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 6 months affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in adults with failing Fontan circulation.
What is the current status of trial NCT06762964?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2025-05-16. Estimated completion is 2027-02.
What conditions does trial NCT06762964 study?
This clinical trial studies the following conditions: HFpEF - Heart Failure With Preserved Ejection Fraction, Single Ventricle Heart Disease, Fontan Circulation.
What interventions are being tested in trial NCT06762964?
The interventions under investigation include: Dapagliflozin tablet (DRUG), Placebo Tablet (DRUG).
Who is sponsoring clinical trial NCT06762964?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06762964 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HFpEF - Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tailored Exercise Training Study Among Adults With HFpEF
RECRUITING · Phase 2
-
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
RECRUITING · Phase 2
-
MOVE-HF MOtivating Physical Activity With BehaVioral Economics in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
HEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
US Benchmarking Clinical Study
RECRUITING
-
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI